2008-07-02 16:37:16 - www.companiesandmarkets.com adds new report - XOMA Limited - Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/XOMA-Limited ..
Introduction

XOMA is a biopharmaceutical company focusing on the discovery and development of therapeutic antibodies for the treatment of cancer and immune diseases. The company has a broad technology platform and a fully integrated product development infrastructure for antibodies and other biologics.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial

trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

XOMA´s technological platform makes the company unique from its competitors. The company´s marketed product, Lucentis was developed using its BCE technology and XOMA 052 is the first candidate being developed using another proprietary technology, Human Engineered (HE) technology.



The company derives its revenues from contract, licensing, collaboration and royalties. These include upfront and milestone payments related to the outlicensing agreement with Merck & Co as well as from contracts entered with SPRI, Taligen, AVEO and NIAID, Genentech and Novartis.



During 2006-2010, XOMA´s revenues are expected to grow at a CAGR of 39% rising from $29 million to $110 million, over the period 2006-2010, XOMA´s biggest contributor to sales growth out to 2010 will be from contract, license and collaboration, forecasted to grow at a CAGR of 43% from $19 million in 2006 to $81 million in 2010.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization